Biovaxys Technology Valuation
| BVAXF Stock | USD 0.04 0 7.19% |
Biovaxys Technology seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Biovaxys Technology Corp from analyzing the firm fundamentals such as Shares Owned By Insiders of 18.94 %, return on equity of -0.73, and Current Valuation of 11.35 M as well as examining its technical indicators and probability of bankruptcy. . In general, most investors favor locking in undervalued instruments and disposing overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Overvalued
Today
Please note that Biovaxys Technology's price fluctuation is out of control at this time. Calculation of the real value of Biovaxys Technology Corp is based on 3 months time horizon. Increasing Biovaxys Technology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Biovaxys otc stock is determined by what a typical buyer is willing to pay for full or partial control of Biovaxys Technology Corp. Since Biovaxys Technology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biovaxys OTC Stock. However, Biovaxys Technology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.04 | Real 0.0365 | Hype 0.04 |
The real value of Biovaxys OTC Stock, also known as its intrinsic value, is the underlying worth of Biovaxys Technology Corp OTC Stock, which is reflected in its stock price. It is based on Biovaxys Technology's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Biovaxys Technology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Biovaxys Technology Corp helps investors to forecast how Biovaxys otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biovaxys Technology more accurately as focusing exclusively on Biovaxys Technology's fundamentals will not take into account other important factors: Biovaxys Technology Total Value Analysis
Biovaxys Technology Corp is currently anticipated to have takeover price of 11.35 M with market capitalization of 8.73 M, debt of 0, and cash on hands of 39.05 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Biovaxys Technology fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
11.35 M | 8.73 M | 0 | 39.05 K |
Biovaxys Technology Asset Utilization
One of the ways to look at asset utilization of Biovaxys is to check how much profit was generated for every dollar of assets it reports. Biovaxys Technology Corp shows a negative utilization of assets of -0.38 percent, losing $0.003779 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Biovaxys Technology Corp shows how discouraging it operates for each dollar spent on its assets.Biovaxys Technology Ownership Allocation
Biovaxys Technology holds a total of 106.72 Million outstanding shares. Biovaxys Technology Corp shows 18.94 percent of its outstanding shares held by insiders and 0.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Biovaxys Technology Profitability Analysis
Net Loss for the year was (6.46 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Biovaxys Technology's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Biovaxys Technology and how it compares across the competition.
About Biovaxys Technology Valuation
The otc valuation mechanism determines Biovaxys Technology's current worth on a weekly basis. Our valuation model uses a comparative analysis of Biovaxys Technology. We calculate exposure to Biovaxys Technology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biovaxys Technology's related companies.BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320 and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. BIOVAXYS TECHNOLOGY is traded on OTC Exchange in the United States.
8 Steps to conduct Biovaxys Technology's Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Biovaxys Technology's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Biovaxys Technology's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Biovaxys Technology's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Biovaxys Technology's revenue streams: Identify Biovaxys Technology's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Biovaxys Technology's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Biovaxys Technology's growth potential: Evaluate Biovaxys Technology's management, business model, and growth potential.
- Determine Biovaxys Technology's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Biovaxys Technology's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Biovaxys Technology Growth Indicators
Investing in growth stocks can be very risky. If the company such as Biovaxys Technology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 92.2 M | |
| Retained Earnings | -8 M |
Complementary Tools for Biovaxys OTC Stock analysis
When running Biovaxys Technology's price analysis, check to measure Biovaxys Technology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biovaxys Technology is operating at the current time. Most of Biovaxys Technology's value examination focuses on studying past and present price action to predict the probability of Biovaxys Technology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biovaxys Technology's price. Additionally, you may evaluate how the addition of Biovaxys Technology to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |